Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2.

Interleukin 2 (IL-2) immunotherapy has met with limited success in the treatment of renal cell carcinoma (RCC) and malignant melanoma (MM). However, non-responders still account for up to 80% of those patients receiving IL-2. A high concentration of soluble IL-2 receptor (sIL-2R) is commonly found i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gooding, R., Riches, P., Dadian, G., Moore, J., Gore, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033994/
https://www.ncbi.nlm.nih.gov/pubmed/7640231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033994/
https://www.ncbi.nlm.nih.gov/pubmed/7640231

Ejemplares similares